BeiGene, Ltd. (HKG:6160)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
152.20
+0.70 (0.46%)
Apr 24, 2025, 4:08 PM HKT
91.09%
Market Cap 208.76B
Revenue (ttm) 29.60B
Net Income (ttm) -5.01B
Shares Out n/a
EPS (ttm) -47.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,643,352
Average Volume 7,336,364
Open 149.70
Previous Close 151.50
Day's Range 148.40 - 154.50
52-Week Range 85.00 - 178.00
Beta 0.49
RSI 53.59
Earnings Date May 14, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 11,000
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6160
Full Company Profile

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD Financial Statements

News

BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit

BeiGene Ltd (NASDAQ: ONC) on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer ....

20 days ago - Benzinga

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...

24 days ago - Business Wire

China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer

BeiGene's Tevimbra wins FDA approval for ... Full story available on Benzinga.com

7 weeks ago - Benzinga

Q4 2024 Beigene Ltd Earnings Presentation Transcript

Q4 2024 Beigene Ltd Earnings Presentation Transcript

7 weeks ago - GuruFocus

BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion

BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion

2 months ago - GuruFocus

BeiGene reports Q4 results

2 months ago - Seeking Alpha

Hang Seng Index left untouched, but tweaks made to tech, China enterprises indices

Tencent Music and Horizon Robotics added to Hang Seng Tech Index, while ZTO Express and BeiGene added to Hang Seng China Enterprises Index.

2 months ago - South China Morning Post

BeiGene (ONC) Stock Rises on Nomura's Optimistic Outlook

BeiGene (ONC) Stock Rises on Nomura's Optimistic Outlook

2 months ago - GuruFocus

ImmunityBio announces collaboration with Beigene

ImmunityBio partners with BeiGene for Phase 3 trial combining tislelizumab and ANKTIVA to improve survival in non-small cell lung cancer patients.

3 months ago - Seeking Alpha

BeiGene Stock Meets 80-Plus RS Rating Benchmark

BeiGene ADR sees its Relative Strength Rating move into the 80-plus level.

3 months ago - Investor's Business Daily

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

BASEL, Switzerland--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appoi...

3 months ago - Business Wire

BeiGene (BGNE) Stock Rises on FDA Approval for Cancer Treatment

BeiGene (BGNE) Stock Rises on FDA Approval for Cancer Treatment

4 months ago - GuruFocus

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...

4 months ago - Business Wire

BeiGene (BGNE) Announces Ticker Change to ONC Effective January 2025

BeiGene (BGNE) Announces Ticker Change to ONC Effective January 2025

4 months ago - GuruFocus

BeiGene Ltd (BGNE) Announces Ticker Symbol Change to "ONC" in 2025

BeiGene Ltd (BGNE) Announces Ticker Symbol Change to "ONC" in 2025

4 months ago - GuruFocus

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announ...

4 months ago - Business Wire

BeiGene Ltd (BGNE) Announces Global Licensing Agreement for Novel Cancer Treatment

BeiGene Ltd (BGNE) Announces Global Licensing Agreement for Novel Cancer Treatment

4 months ago - GuruFocus

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...

4 months ago - Business Wire

Baker Bros. Advisors LP's Strategic Acquisition of BeiGene Ltd Shares

Baker Bros. Advisors LP's Strategic Acquisition of BeiGene Ltd Shares

4 months ago - GuruFocus

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, furthe...

4 months ago - Financial Post